Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis
NCT01330901
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
22
Enrollment
OTHER
Sponsor class
Conditions
Ankylosing Spondylitis
Interventions
DRUG:
Ustekinumab
Sponsor
Charite University, Berlin, Germany